Article
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Clinical pharmacology and therapeutics - 1 Dec 2013
Caudle K E, Thorn C F, Klein T E, Swen J J, McLeod H L, Diasio R B, Schwab M
Abstract excerpt
The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide...
Topics
- Antimetabolites, Antineoplastic
- Capecitabine
- Deoxycytidine
- Dihydropyrimidine Dehydrogenase Deficiency
- Dihydrouracil Dehydrogenase (NADP)
- Female
- Fluorouracil
- Genotype
- Humans
- Incidental Findings
- Male
- Risk Assessment
- Sex Factors